SEC Tracker
Get the app

Zeo ScientifiX ZEOX

Zeo ScientifiX Q1 FY26: revenue $1.4M, up 33%; diluted EPS −$0.12

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Zeo ScientifiX reported for Q1 FY26, the quarter ended Jan 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.4M+33% from $1.1M in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$852KAgainst −$1.2M in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$0.12Against −$0.20 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$1.0M+43% from $720K in Q1 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$471K−825% from $65K in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Zeo ScientifiX files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Sunshine Biopharma SBFM public float $7M, Jun 30, 2025
  2. Neuphoria Therapeutics NEUP public float $7M, Dec 31, 2025
  3. CV Sciences CVSI public float $7M, Jun 30, 2025
  4. Minerva Neurosciences NERV public float $7M, Jun 30, 2025
  5. Bolt Biotherapeutics BOLT public float $7M, Jun 30, 2025